U.S.-South Africa Program for Collaborative Biomedical Research Phase 3 (HIV/AIDS) (R01 Clinical Trial Optional)

The NIH’s U.S.-South Africa Program for Collaborative Biomedical Research Phase 3 (HIV/AIDS) (RFA-AI-24-023) seeks to fund research that addresses critical areas in HIV/AIDS, including co-morbidities, co-infections, implementation science, and data science related to HIV/AIDS. This program focuses on fostering international collaboration between South African and U.S. investigators to drive scientific advancements, share innovative technologies, and respond to public health priorities tied to the global HIV/AIDS crisis. The maximum award amount is set at $400,000, but the NIH has not specified a total funding allocation or the expected number of awards. Eligible applicants include both U.S. and non-U.S. organizations, with a specific focus on supporting collaborations with South African entities. However, non-U.S. components of U.S.-based organizations are not eligible to apply independently. Applications must be submitted by March 12, 2025, following the posting date of September 17, 2024. For comprehensive eligibility and submission guidelines, applicants are advised to review the full funding opportunity announcement or contact NIH Grants Information.